

Santen Incorporated

[View the current Santen Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/29577-Santen+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/29577-Santen+Incorporated.html>)

Contact Details:

555 Gateway Drive

Napa

California

94558

United States of America

Tel: 707 254 1750

Fax: 707 254 3648

Email: info@santeninc.com

Santen Incorporated, a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd., opened its doors in the San Francisco Bay Area in 1993. Located in Northern California's Napa Valley, the U.S. office is comprised of established, highly experienced healthcare professionals, led by President and CEO, Adrienne Graves, PhD. On average, each member of the U.S. senior management team has 20 or more years of industry experience, with extensive knowledge and expertise based exclusively in the ophthalmic field. The leading ophthalmic pharmaceutical company in Japan since 1890, Santen specializes in treatments for eye and rheumatic diseases, offering both prescription and over-the-counter (OTC) products.

In early 2004, Santen entered into a partnership agreement with VISTAKON® Pharmaceuticals, LLC, granting VISTAKON the exclusive U.S. distribution rights to the established Santen ophthalmic products QUIXIN® (levofloxacin ophthalmic solution) 0.5%, BETIMOL® (timolol ophthalmic solution) 0.25% and 0.5%, and ALAMAST® (pemirolast potassium ophthalmic solution) 0.1%. This synergistic arrangement will enable Santen to move forward with a renewed emphasis on the discovery and development of exciting new products that will make a significant difference in eye care.

Recent Publications by Santen Incorporated:



- [Cyclosporin A eye drops inhibit fibrosis and inflammatory cell infiltration in murine type I allergic conjunctivitis without affecting the early-phase reaction.](#)

PURPOSE: To understand the mechanisms of action of cyclosporin A eye drops...11th November, 2009

Research and Development Center, Santen Pharmaceutical Co., Ltd., 8916-16- Curr Eye Res. 2009 Jun;34(6):426-37.

- [Transient receptor potential vanilloid 1 agonists as candidates for anti-inflammatory and immunomodulatory agents.](#)

- We recently demonstrated that SA13353...*3rd November, 2009
 Research and Development Center, Santen Pharmaceutical Co., Ltd., 8916-16- Eur J Pharmacol. 2009 Oct 28. ([DOI Direct Link](#))
- [Ocular hypotensive effects of anti-glaucoma agents in mice.](#)
*PURPOSE: To evaluate the ocular hypotensive effects induced by topical...*28th October, 2009
 Research and Development Center, Santen Pharmaceutical Co. Ltd., Nara,- J Ocul Pharmacol Ther. 2009 Oct;25(5):401-8. ([DOI Direct Link](#))
 - [Cyclosporine A eye drops inhibit the early-phase reaction in a type-I allergic conjunctivitis model in mice.](#)
*PURPOSE: The effects of cyclosporine A eye drops on the early-phase...*22nd October, 2009
 Research and Development Center, Santen Pharmaceutical Co. Ltd.,- J Ocul Pharmacol Ther. 2009 Aug;25(4):321-8. ([DOI Direct Link](#))
 - [Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.](#)
*The disposition and metabolism of tafluprost, an ester prodrug of the...*20th October, 2009
 Non-clinical Research Group, Research and Development Center, Santen- Drug Metab Dispos. 2009 Aug;37(8):1622-34. Epub 2009 May 28. ([DOI Direct Link](#))
 - [Point mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augments collagen-induced arthritis in DBA/1J mice.](#)
*BACKGROUND: Knock-in mice (gp130F759) with a Y759F point mutation in...*20th May, 2009
 Research and Development Center, Santen Pharmaceutical Co, Ltd, Ikoma-shi,- BMC Musculoskelet Disord. 2009 Feb 19;10:23. ([DOI Direct Link](#))
 - [Ophthalmic timolol in a hydrogel vehicle leads to minor inter-individual variation in timolol concentration in aqueous humor.](#)
*Ophthalmic timolol has been used for decades in the treatment of glaucoma...*31st March, 2009
 Institute of Biomedicine, Pharmacology, University of Helsinki, Helsinki,- Eur J Pharm Sci. 2009 Feb 15;36(2-3):292-6. Epub 2008 Nov 1. ([DOI Direct Link](#))
 - [Synthesis of novel 1,4-benzoxazin-3-one derivatives as inhibitors against tyrosine kinases.](#)
*We designed and synthesized a novel 1,4-benzoxazin-3-one derivative 4...*28th March, 2009
 Research and Development Center, Santen Pharmaceutical Co. Ltd, 8916-16- Bioorg Med Chem. 2009 Jan 15;17(2):699-708. Epub 2008 Dec 6. ([DOI Direct Link](#))
 - [Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost.](#)
*BACKGROUND: Some studies have shown that benzalkonium chloride (BAK), a...*20th March, 2009
 Santen- Ophthalmic Res. 2009;41(2):118-22. Epub 2009 Jan 16. ([DOI Direct Link](#))
 - [The investigation of synovial genomic targets of bucillamine with microarray technique.](#)
*OBJECTIVE: To identify the molecular mechanisms of bucillamine activity...*18th March, 2009
 Research & Development Center, Santen Pharmaceutical Co., Ltd., 8916-16- Inflamm Res. 2009 Sep;58(9):571-84. Epub 2009 Mar 17. ([DOI Direct Link](#))
 - [Synthesis and biological evaluation of N-mercaptoacylcysteine derivatives as leukotriene A4 hydrolase inhibitors.](#)
*We studied synthetic modifications of N-mercaptoacylamino acid derivatives...*3rd March, 2009
 Nara Research & Development Center, Santen Pharmaceutical Co., Ltd,- Bioorg Med Chem Lett. 2009 Jan 15;19(2):442-6. Epub 2008 Nov 18. ([DOI Direct Link](#))
 - [Synthesis and biological evaluation of N-mercaptoacylproline and N-mercaptoacylthiazolidine-4-carboxylic acid derivatives as leukotriene A4 hydrolase inhibitors.](#)
*We studied the synthetic modification of structurally similar...*17th December, 2008
 Nara Research & Development Center, Santen Pharmaceutical Co., Ltd,- Bioorg Med Chem Lett. 2008 Aug 15;18(16):4529-32. Epub 2008 Jul 15. ([DOI Direct Link](#))
 - [Ocular pharmacokinetic/pharmacodynamic modeling for multiple anti-glaucoma drugs.](#)
*We have constructed a new ocular pharmacokinetic pharmacodynamic (PK/PD)...*1st October, 2008
 Santen Pharmaceutical- Biol Pharm Bull. 2008 Aug;31(8):1590-5.
 - [Altered distribution of aquaporin 5 and its C-terminal binding protein in the lacrimal glands of a mouse](#)

[model for Sjogren's syndrome.](#)

PURPOSE: To investigate the distribution and expression of aquaporin 5... 24th September, 2008
Department of Ophthalmology, Keio University School of Medicine, Tokyo,- Curr Eye Res. 2008
Aug;33(8):621-9. ([DOI Direct Link](#))

Press Releases on Santen Incorporated:

Reportlinker Adds Blood Banking and Blood Products - Global Market Perspective	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Blood Banking and Blood Products - Global Market Perspective http://www
Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference	24th November, 2009	Quest Diagnostics	MADISON, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is
Prodesse's ProParaflu+(TM) Assay Cleared for US Marketing by FDA	24th November, 2009	Gen-Probe Incorporated	Michael Watts Vice president, investor relations and corporate communications 858-410-8673 SOURCE Gen-Probe Incorporated
Aflac To Exchange Two Lloyds Banking Group Securities, Enhance Risk-Based Capital Ratio	24th November, 2009	Aflac Incorporated	COLUMBUS, Ga., Nov. 24 /PRNewswire-FirstCall/ -- Aflac Incorporated (NYSE: AFL) announced today that the Lloyds Banking Group plc has accepted the exchange of two of its investment securities owned by
WellTek Positioned to Capitalize on Trends in Health and Fitness	24th November, 2009	WellTek Incorporated	ORLANDO, Fla., Nov. 24 /PRNewswire-FirstCall/ -- Two thirds of adults are overweight and one third of those are obese. Experts estimate that 80 percent of the population will experience a back

BioNews Results for Santen Incorporated



- [CEO of Napa-Based Santen Inc. Joins Glaucoma Research Foundation Board](#)
Pharma Live: Nov 5 2009 6:26PM Matching: santen
- [Santen CEO Adrienne Graves Joins Board Of Glaucoma Research Foundation](#)
Medical News Today: Nov 4 2009 6:16AM Matching: santen
- [Medical News: Santen CEO Adrienne Graves Joins Board Of Glaucoma Research Foundation](#)
Medical News Today: Nov 3 2009 3:12PM Matching: santen
- [Medical News: Santen CEO Adrienne Graves Joins Board Of Glaucoma Research Foundation](#)
Medical News Today: Nov 3 2009 3:10PM Matching: santen
- [CBI Announces the Agenda for Their West Coast Forum on Clinical Supply Chain Management](#)
PR Newswire via Yahoo!: Sep 11 2009 12:22PM Matching: santen
- [Merck & Co launches Saflutan in UK, Spain](#)
PharmaBiz: Sep 5 2009 5:11AM Matching: santen
- [Merck Launches SAFLUTAN \(tafluprost\) in International Markets](#)
Stockwatch: Sep 3 2009 8:12AM Matching: santen
- [Merck eye drug launched in U.K., Spain](#)
Philadelphia Inquirer: Sep 3 2009 7:34PM Matching: santen

Santen Incorporated Patents:



- 6221846- [Ophthalmic drug compositions](#)
- 6488938- [Polylactic acid scleral plug](#)
- 6492369- [Therapeutic agents for drug dependence](#)
- 6492370- [Urea derivatives and pharmaceutical compositions thereof](#)
- 6534499- [N-substituted-N'-substituted urea derivatives and the use thereof as TNF-.alpha. production inhibitory agents](#)
- 6576668- [Remedies for arthrosis deformans](#)
- 6645936- [Reducing postoperative astigmatism](#)
- 6683200- [N-substituted-N'-substituted urea derivatives and pharmaceutical compositions containing the derivatives](#)
- 6713472- [Thiazine or pyrazine derivatives](#)
- 6730784- [Urea derivatives useful as synthetic intermediates](#)
- 6746744- [Sealing label](#)
- 6479627- [Aqueous preparation of lactoferrin having improved stability](#)
- 6465588- [Four component copolymers and the ocular lens made thereof](#)
- 6444705- [Angiogenesis inhibitors](#)
- 6242476- [Leukotriene A4 hydrolase inhibitors](#)
- 6252046- [Polypeptide having water channel activity and DNA sequence](#)
- 6268511- [Itaconate derivatives used for a component of a polymer](#)
- 6281208- [Therapeutic agent for glaucoma](#)
- 6281224- [Pranoprofen eyedrops containing organic amine](#)
- 6288049- [Fluorometholone ophthalmic suspension](#)
- 6329547- [Vinylbenzene derivatives](#)
- 6395932- [1,2-diphenyl-2-propen-1-one derivatives](#)
- 6410576- [Thiazolidine derivatives](#)

- 6420398- [Urea derivatives having nitrogen aromatic heterocycle](#)
- 6780983- [Polypeptide having water channel activity and DNA sequence](#)
- 6833358- [Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides](#)
- 7348329- [Therapeutic agent for keratoconjunctival disorder](#)
- 7358255- [Therapeutic agent for keratoconjunctival disorder](#)
- 7410987- [Method for treating pain or pruritis by administering .kappa.-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative](#)
- 7422326- [Monkey visual field measurement system and visual field measurement method](#)
- 7438704- [Open instillation container and method of manufacturing the container](#)
- 7455855- [Delivering substance and drug delivery system using the same](#)
- 7491739- [TNF-.alpha. production inhibitors](#)
- 7503909- [Instillation container with level-difference portion](#)
- 7534802- [Compounds having 4-pyridylalkylthio group as substituent](#)
- 7544703- [Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein](#)
- 7345064- [TNF-.alpha. production inhibitors](#)
- 7325440- [Hole inspection system for a pierced container](#)
- 7232881- [Peptide containing Ser-Ser-Ser-Arg](#)
- 6875201- [Recessed part forming instillation container](#)
- 6960575- [Thiazine derivatives](#)
- 6969524- [Interferon complex and medicinal use thereof](#)
- 6984629- [Ectocornea extension promoters](#)
- 7055692- [Packaging body](#)
- 7071166- [Skin wound healing promoters](#)
- 7098226- [TNF-.alpha. production inhibitors](#)
- 7112598- [.kappa. opioid receptor agonist comprising 2-phenylbenzothiazoline derivative](#)
- 7114635- [Contamination preventive cap](#)
- 7147844- [System for stabilizing lacrimal fluid layer](#)
- 7563906- [Indazole derivatives](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

